Clinical Trials Logo

Filter by:
NCT ID: NCT04831814 Completed - Clinical trials for Colorectal Neoplasms

Narrow Band Imaging in Diagnosis of Colorectal Polyps

Start date: April 4, 2019
Phase: N/A
Study type: Interventional

Optical diagnosis of colorectal polyps is a promising tool to avoid risks of unnecessary polypectomies and to save costs of tissue pathology. NICE (NBI International Colorectal Endoscopic) and WASP (Workgroup on Serrated Polyps and Polyposis) classification were developed for diagnosis of adenomatous and sessile serrated polyps, respectively.

NCT ID: NCT04818450 Completed - Critically Ill Clinical Trials

Impact of Gabapentin on Slow Wave Sleep in Adult Critically Ill Patient

GASWAC
Start date: April 19, 2021
Phase: N/A
Study type: Interventional

The investigators proposed that gabapentin will increase slow-wave sleep in adult critically ill patients. Increasing slow-wave sleep will improve the patients' outcomes (shortening ICU length of stay, improving ventilator free days, increasing delirium free days) in critically ill patients, a university hospital, Thailand.

NCT ID: NCT04797195 Completed - Clinical trials for Kidney Failure, Chronic

Improving Care for Peritoneal Dialysis Patients With the CKD-PD App

Start date: December 13, 2021
Phase: N/A
Study type: Interventional

Managing the hydration status in patients undergoing peritoneal dialysis (PD) is a key task for nephrologists in Thailand that is made difficult due to lack of timely access to hydration metrics including weight, blood pressure, and ultrafiltration volume. This research project aims to improve the monitoring of hydration status in PD patients from a bimonthly, in-clinic review of a handwritten log-book to a smart phone based app (CKD-PD) with digitized data that allows for near real time monitoring hydration abnormalities, thereby creating the opportunity for earlier treatment of overhydration. The investigators hypothesize that use of the CKD-PD will improve early treatment of overhydration, and potentially reduce the incidence of complications, hospitalizations, and mortality in PD patients.

NCT ID: NCT04792424 Completed - Clinical trials for Continuous Renal Replacement Therapy

No Monitoring of Post-filter Ionized Calcium in Regional Citrate Anticoagulation

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Do no monitor of post-circuit ionized calcium affact the filter life time of continueous renal replacement therapy with regional citrate anticoagulation circuit? A randomized control trial

NCT ID: NCT04788108 Completed - Threatened Abortion Clinical Trials

Oral Progesterone for Prevention of Miscarriage in Threatened Abortion

Start date: August 1, 2021
Phase: Phase 4
Study type: Interventional

This study evaluates the effectiveness of oral dydrogesterone in preventing miscarriage in threatened abortion. Half of participants will receive oral dydrogesterone, while the other half will receive oral placebo.

NCT ID: NCT04781244 Completed - Cryotherapy Effect Clinical Trials

Cost-effectiveness of EndWarts® FREEZE - an Alternative Home Cryotherapy Device for Wart Treatment

Start date: November 12, 2020
Phase: N/A
Study type: Interventional

This study aimed to study cost-effectiveness of EndWarts® FREEZE for wart treatment, compared to conventional liquid nitrogen cryotherapy

NCT ID: NCT04774016 Completed - Iron Absorption Clinical Trials

Iron Absorption From an Iron-fortified Follow-up Formula With Added Synbiotic or Human Milk Oligosaccharides

Start date: November 18, 2020
Phase: N/A
Study type: Interventional

The co-primary objectives of this study are: 1) to investigate the effect adding a synbiotic (combination of a pre-and probiotic) to iron-fortified follow-up formula (FUF) on iron bioavailability, and 2) to investigate the effect adding Human Milk Oligosaccharides (HMOs) to iron-fortified FUF on iron bioavailability in 10-14 month-old Thai children.

NCT ID: NCT04771481 Completed - Effect of Drug Clinical Trials

Metoclopramide for Acute Upper GI Bleeding

Start date: April 10, 2021
Phase: Phase 4
Study type: Interventional

The presence of blood clot in stomach limited quality of endoscopic view ,which affect successful rate of hemostatic endoscopy in patient with acute upper gastrointestinal bleeding. The study is aimed to evaluate the efficacy of metoclopramide, as pro-kinetic agent ,for gastric visualization in the patient with acute UGIB; double-blind randomized controlled trial and two centers study. The patient were randomly assigned to receive either metoclopramide (10mg) intravenously or placebo before endoscopy 30-120 min. The primary endpoint was endoscopic yield, assessed by objective gastric visualized scoring systems. Secondary end points include duration of endoscope, technical success rate, the need for second-look EGD, units of blood transfusion, length of hospital stay and 30-day rebleeding rate.

NCT ID: NCT04768725 Completed - Obesity Clinical Trials

Combined Physical-cognitive Exercise and Dietary Intervention for Postmenopausal Obese Women

Start date: September 26, 2021
Phase: N/A
Study type: Interventional

This study aims to examine the effects of dietary intervention combined with physical-cognitive exergaming on cognitive performance and circulating biomarkers of obese postmenopausal women. It is hypothesized that participants will demonstrate significant improvement in cognitive performance and circulating biomarkers after participating in this combined program compared to baseline and the dietary and control groups.

NCT ID: NCT04764422 Completed - Covid-19 Clinical Trials

Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand

Start date: March 20, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study will be conducted in 2 phases. Phase 1 designed to evaluate safety, tolerability and immunogenicity COVID-19 vaccine (NDV-HXP-S) administered at different doses levels (1, 3, and 10 µg) without adjuvant, and at two different dose levels (1 and 3 µg) with the adjuvant CpG 1018 among healthy adults, (age 18-59 years) (210 subjects). Subjects will receive 2 doses of assigned investigational product (IP) on D1 and D29 (V1 and V3), and be assessed in clinic for safety and reactogenicity at 7 days after each vaccination (day 1 as day vaccination). An interim analysis of Phase 1 data will be conducted as the basis for decisions about advancement to Phase 2 of the study and about treatment group down selection. Phase 2 (250 subjects) will include approximately one-third subjects with age 60-75 years.